

# Control of Hyperglycaemia in Paediatric intensive care

No.1

September 2008

# Welcome to the first CHiP newsletter!

We hope you find the newsletter informative and interesting. We welcome your feedback and encourage you to contribute to future publications with any experiences or issues you would like to share with everyone.


# **CHiP Sites**

Since the beginning of May we have seen a steady increase in the number of sites coming on board. To date the study sites that are up and running include:

- Birmingham
- Bristol
- Royal Bromprton
- Manchester
- St Mary's
- Sheffield
- Southampton

We expect Great Ormond Street, Stoke on Trent and Leeds to be up and running soon.

A new possible CHiP site is Leicester.



Map of the participating and potential CHiP study sites.


# **Research Nurse Study Day**

A reminder for all CHiP Research Nurses that the study day will be held at Birmingham Children's Hospital Education Centre on Monday 29<sup>th</sup> September 2008, 10:00 -18:00.

## Recruitment

The first patient was randomised on 4th May 2008: Well done Helen and Lucy in Southampton!

At the end of August 2008 we had <u>59</u> patients recruited into the trial. The graph below shows that we are behind with the expected level of recruitment but we hope that this will pick up after the summer and with increased experience of the research nurses and PICU staff.



The expected versus the actual rate of recruitment for the CHiP trial on a monthly basis (a site's expected recruitment is only included once they have started screening patients).

# Who's Who on the CHiP trial

### **<u>Dr Duncan Macrae - Chief Investigator</u>**



commercial trials of the use of sildenafil and inhaled nitric oxide in pulmonary hypertension.

Dr Macrae also carries out the role of Paediatric Editor for the journal of Intensive Care Medicine and is an Associate Editor of Paediatric Critical Care Medicine.

"Although I have been involved in the investigation of some very invasive techniques, such as ECMO and iNO, I base my clinical practice on the mantra 'Keep it simple'. Management of glycaemia is a simple intervention which we can all do well. We simply had no idea until the adult 'Leuven' studies that it might be at all important to suppress the glycaemic response to stress and critical illness. So the CHiP trial is in a sense taking the management of multiorgan-system dysfunction back to basics, and (re)introducing a 'simple' intervention." - Dr Duncan Macrae.